Sangamo Therapeutics Inc (SGMO) FY2025Q2 Earning Prediction
Sangamo Therapeutics Inc (SGMO) is set to release its earnings performance on 08/07 16:00:00 ET in After Hours trading. Consensus forecasts predict a revenue of 31.68M and an earnings per share (EPS) of -0.07 for the . With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!
Earnings Surprise Analysis
SGMO Transcript
The earnings call highlighted strong financial metrics, including a sufficient cash runway into 2026 and positive clinical data across multiple programs. While the Q&A revealed some uncertainties in partnership negotiations, the FDA's supportive stance on the Fabry disease program and ongoing interest in other platforms provide optimism. The call's overall tone was positive, with strong clinical results and financial health suggesting a likely stock price increase of 2% to 8% over the next two weeks.
The earnings call summary indicates strong financial performance with an $18 million upfront fee from Eli Lilly and potential for $1.4 billion in future earnings. The Fabry program shows significant clinical progress, with patients showing improved quality of life and stable cardiac function. The Q&A section reveals positive sentiment from analysts and high potential adoption rates for ST-920. Despite an equity offering, the cash runway is extended, and cost reductions are significant. Overall, the optimistic guidance and strong clinical data suggest a positive stock price movement.
The overall sentiment is negative due to the equity offering, which typically dilutes existing shares, and the lack of clear guidance on partnerships and statistical analysis. Although there are positive aspects like reduced expenses and potential partnerships, the uncertainty in partnership success, macroeconomic concerns, and unclear management responses in the Q&A contribute to a negative outlook.
The earnings call summary highlights some positive aspects, such as reduced operating expenses, a promising regulatory pathway for Fabry disease, and potential partnerships. However, the equity offering and dependency on partnerships to secure funding may raise concerns. The Q&A section reveals management's reluctance to provide specifics, which could worry investors. Considering these factors, along with the equity offering's potential negative impact, the overall sentiment leans towards neutral, with a slight risk of negative sentiment if partnership talks falter or financial uncertainties persist.
SGMO Slides
SGMO Report
Frequently Asked Questions
What is the Sangamo Therapeutics Inc FY2025Q2 Earnings Release Date and Time?
Sangamo Therapeutics Inc (SGMO) is scheduled to release its FY2025Q2 earnings report onAug 7, 2025, After Hours(approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.
What Are the Consensus Forecasts for Sangamo Therapeutics Inc FY2025Q2 Revenue and EPS?
Analysts' consensus predicts 31.68M in revenue and an EPS of -0.07 for Sangamo Therapeutics Inc's FY2025Q2.
What Does Intellectia's AI Predict for Sangamo Therapeutics Inc FY2025Q2 Earnings?
Intellectia's exclusive AI algorithms forecast a forSangamo Therapeutics Inc's FY2025Q2 earnings, with a prediction date of Aug 7, 2025. Sangamo Therapeutics Inc
How Can I Use This Earnings Prediction to Trade SGMO Stock?
Leverage Intellectia's AI forecast to position trades ahead of theAug 7, 2025 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.
How Accurate Is Intellectia's AI for Earnings Predictions Like Sangamo Therapeutics Inc FY2025Q2?
Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.
How does AI Earnings Prediction generate its forecasts?
AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!
When are the predictions available, and how often are they updated?
Predictions are generated two days before a company’s earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They’re updated in real-time if significant news breaks, ensuring you get fresh insights.
Can I use AI Earnings Prediction for all types of stocks?
Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2025-2026 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!
